News

Published on 13 Nov 2023 on GuruFocus.com via Yahoo Finance

Meta Platforms Inc Takes a Hit in Jeremy Grantham's Latest Portfolio Adjustments

Article preview image

Grantham's Q3 Moves Reflect Strategic Shifts Amid Market Dynamics

Jeremy Grantham (Trades, Portfolio), the seasoned investment strategist and co-founder of Grantham Mayo van Otterloo (GMO) LLC, has made notable changes to his investment portfolio in the third quarter of 2023. Known for his expertise in identifying market bubbles and his cautious approach to investing, Grantham's latest 13F filing reveals a series of strategic buys, sells, and adjustments reflective of his ongoing analysis of market conditions.

Warning! GuruFocus has detected 5 Warning Sign with MSFT.

Read the rest of the article
NASDAQ.META price evolution
NYSE.NVS price evolution
SIX.NOVN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Novartis’ Gene Therapy Shows Promise in Treating SMA

Novartis ( (NVS) ) has provided an update. Novartis announced the success of its Phase III STEER ...

TipRanks · via Yahoo Finance 31 Dec 2024
Why Is Novartis AG (NVS) Among the Best European Dividend Stocks To Buy Now?

We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we a...

Insider Monkey · via Yahoo Finance 23 Dec 2024
European Health Stocks Brace for Year Clouded by US Politics

(Bloomberg) -- After falling off their perch in the last few months of 2024, European healthcare...

Bloomberg · via Yahoo Finance 19 Dec 2024
Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now

We recently compiled a list of the 10 Oversold Global Stocks To Buy Right Now. In this article, w...

Insider Monkey · via Yahoo Finance 18 Dec 2024
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Voyager Therapeutics, Inc. price-consensus-chart | Voyager Therapeutics, Inc. Quote VYGR also...

Zacks · via Yahoo Finance 18 Dec 2024
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right...

Luckily, most ETFs are very... (SAP) accounts for about 4.54% of the fund's total assets, followe...

Zacks · via Yahoo Finance 5 Dec 2024
5 High-Yielding Stocks Addressing the U.N. Sustainable Development Goals

If you want some signals of where the world is moving, check out the United Nation’s Sustainable...

Morningstar 4 Dec 2024
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Novartis NVS has entered into a global license and collaboration agreement with PTC Therapeutics...

Zacks · via Yahoo Finance 3 Dec 2024
Wall St set for flat open as caution prevails in data-packed week

Wall Street's main indexes were set for a flat open on Monday, with focus on a slew of economic d...

Reuters · via AOL 2 Dec 2024
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For...

On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaborat...

Benzinga · via Yahoo Finance 2 Dec 2024

Copyright Statfolio @ 2025

Social Accounts